Study of Oral Fampridine-SR in Multiple Sclerosis

• Status: Completed
• Trial end date: 2006-09-01
• Target enrollment: 0
• Participant gender: All

Summary

To assess the safety and efficacy of 10 milligram (mg) twice a day (b.i.d.) Fampridine-SR in patients diagnosed with multiple sclerosis (MS), in a double-blind, placebo-controlled, parallel group study.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Acorda Therapeutics
• Treatments: 4-Aminopyridine

Criteria

Inclusion Criteria:

• Have a confirmed diagnosis of multiple sclerosis

• Are able to walk with or without an assistive device

Exclusion Criteria:

• Pregnancy, breastfeeding or females of childbearing potential not using adequate birth control

• Participating in other investigational drug trials

• A medical history or clinical findings that preclude entry into the study

• A medication history that precludes entry into the study

• Previously treated with 4-aminopyridine (4-AP)